The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy

No AccessJournal of UrologyAdult Urology1 Jun 2015The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy Juan Morote, Antonio Gómez-Caamaño, José L. Alvarez-Ossorio, Daniel Pesqueira, Angel Tabernero, Francisco Gómez Veiga, José A. Lorente, Mariano Porras, Juan J. Lobato, María J. Ribal, Jacques Planas, and ANAMET Investigators Group Juan MoroteJuan Morote Department of Urology, Hospital Vall d’Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain More articles by this author , Antonio Gómez-CaamañoAntonio Gómez-Caamaño Department of Radiation Oncology, Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain More articles by this author , José L. Alvarez-OssorioJosé L. Alvarez-Ossorio Department of Urology, Hospital Universitario Puerta del Mar, Cadiz, Spain More articles by this author , Daniel PesqueiraDaniel Pesqueira Department of Urology, Hospital Universitario Povisa, Pontevedra, Spain More articles by this author , Angel TaberneroAngel Tabernero Department of Urology, Hospital Universitario La Paz, Madrid, Spain More articles by this author , Francisco Gómez VeigaFrancisco Gómez Veiga Department of Urology, Hospital A Coruña, A Coruña, Spain More articles by this author , José A. LorenteJosé A. Lorente Department of Urology, Hospital del Mar, Barcelona, Spain More articles by this author , Mariano PorrasMariano Porras Department of Radiation Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain More articles by this author , Juan J. LobatoJuan J. Lobato Department of Urology, Hospital General Universitario de Alicante, Alicante, Spain More articles by this author , María J. RibalMaría J. Ribal Department of Urology, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain More articles by this author , Jacques PlanasJacques Planas Department of Urology, Hospital Vall d’Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain More articles by this author , and ANAMET Investigators Group More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.12.086AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Androgen deprivation therapy may promote the development of the metabolic syndrome in patients with prostate cancer. We assessed the prevalence of the full metabolic syndrome and its components during the first year of androgen deprivation therapy. Materials and Methods: This observational, multicenter, prospective study included 539 patients with prostate cancer scheduled to receive 3-month depot luteinizing hormone-releasing hormone analogs for more than 12 months. Waist circumference, body mass index, lipid profile, blood pressure and fasting glucose were evaluated at baseline and after 6 and 12 months. The metabolic syndrome was assessed according to NCEP ATP III criteria (2001) and 4 other definitions (WHO 1998, AACE 2003, AHA/NHLBI 2005 and IDF 2005). Results: At 6 and 12 months after the initiation of androgen deprivation therapy, significant increases were observed in waist circumference, body mass index, fasting glucose, triglycerides, total cholesterol, and high-density and low-density lipoprotein cholesterol. No significant changes in blood pressure 130/85 or greater were detected. A nonsignificant increase of 3.9% in the prevalence of the full metabolic syndrome (ATP III) was observed (22.9% at baseline vs 25.5% and 26.8% at 6 and 12 months, respectively). The prevalence of the metabolic syndrome at baseline varied according to the definition used, ranging from 9.4% (WHO) to 50% (IDF). At 12 months significant increases in prevalence were observed with the WHO (4.1%) and AHA/NHLBI (8.1%) definitions. Conclusions: Androgen deprivation therapy produces significant early effects on waist circumference, body mass index, fasting glucose, triglycerides and cholesterol. The prevalence of and increase in the metabolic syndrome depend on the defining criteria. Counseling patients on the prevention, early detection and treatment of specific metabolic alterations is recommended. References 1 : EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol2014; 65: 467. Google Scholar 2 : Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?. Eur Urol2013; 64: 159. Google Scholar 3 : The metabolic syndrome. Lancet2005; 365: 1415. Google Scholar 4 : Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med2006; 119: 812. Google Scholar 5 : Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol2006; 24: 3979. Google Scholar 6 : Androgen deprivation therapy and morbid obesity: do they share cardiovascular risk through metabolic syndrome?. Actas Urol Esp2011; 35: 259. Google Scholar 7 : Metabolic syndrome in patients with prostate cancer undergoing androgen suppression. Actas Urol Esp2014; 38: 285. Google Scholar 8 : Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation2004; 109: 433. Google Scholar 9 : Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA2002; 287: 356. Google Scholar 10 : Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst2010; 102: 39. Google Scholar 11 : Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys2012; 82: 1411. Google Scholar 12 : Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin2010; 60: 194. Google Scholar 13 : Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA2011; 306: 2359. Google Scholar 14 : Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab2006; 91: 1305. Google Scholar 15 : Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer2006; 106: 581. Google Scholar 16 : Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study. Urology2008; 71: 735. Google Scholar 17 : Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology2004; 63: 742. Google Scholar 18 : Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab2002; 87: 599. Crossref, Medline, Google Scholar 19 : The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab2001; 86: 4261. Crossref, Medline, Google Scholar 20 : Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf)2002; 56: 779. Google Scholar 21 : Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond)2003; 104: 195. Google Scholar 22 : Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int2008; 102: 44. Google Scholar 23 : Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol2011; 74: 377. Google Scholar 24 : Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol2013; 189: S34. Link, Google Scholar 25 : Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol1995; 154: 100. Link, Google Scholar 26 : Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer. Cancer2008; 112: 2188. Google Scholar 27 : Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med2005; 257: 167. Google Scholar 28 : The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol2006; 97: 3A. Google Scholar 29 : The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2005; 28: 2289. Google Scholar 30 : Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet2008; 371: 1927. Google Scholar © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byDambal S, Howard L, Allott E, Aronson W, Kane C, Amling C, Cooperberg M, Terris M and Freedland S (2019) Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH DatabaseJournal of Urology, VOL. 203, NO. 1, (120-127), Online publication date: 1-Jan-2020.Griebling T (2018) Re: Depressive Symptoms are Found to be Potential Adverse Effects of Androgen Deprivation Therapy in Older Prostate Cancer Patients: A 15-Month Prospective, Observational StudyJournal of Urology, VOL. 200, NO. 2, (222-223), Online publication date: 1-Aug-2018.Penson D (2016) Re: Association of Androgen Deprivation Therapy with Depression in Localized Prostate CancerJournal of Urology, VOL. 197, NO. 3 Part 1, (703-704), Online publication date: 1-Mar-2017.Griebling T (2016) Re: Metabolic Syndrome Components are Associated with Increased Prostate Cancer RiskJournal of Urology, VOL. 196, NO. 4, (1125-1126), Online publication date: 1-Oct-2016.Taneja S (2016) Re: Long-Term Follow-up of a Randomized Trial of Radiation with or without Androgen Deprivation Therapy for Localized Prostate CancerJournal of Urology, VOL. 195, NO. 5, (1471-1473), Online publication date: 1-May-2016.Pinthus J (2015) Uncovering the Metabolic Complications of Androgen Deprivation Therapy in Patients with Prostate Cancer—Where Do We Take it Next?Journal of Urology, VOL. 193, NO. 6, (1882-1883), Online publication date: 1-Jun-2015. Volume 193Issue 6June 2015Page: 1963-1969 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.Keywordsandrogensmetabolic syndrome Xprostatic neoplasmsAcknowledgmentsBradley Londres provided editorial assistance.Metrics Author Information Juan Morote Department of Urology, Hospital Vall d’Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain More articles by this author Antonio Gómez-Caamaño Department of Radiation Oncology, Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain More articles by this author José L. Alvarez-Ossorio Department of Urology, Hospital Universitario Puerta del Mar, Cadiz, Spain More articles by this author Daniel Pesqueira Department of Urology, Hospital Universitario Povisa, Pontevedra, Spain More articles by this author Angel Tabernero Department of Urology, Hospital Universitario La Paz, Madrid, Spain More articles by this author Francisco Gómez Veiga Department of Urology, Hospital A Coruña, A Coruña, Spain More articles by this author José A. Lorente Department of Urology, Hospital del Mar, Barcelona, Spain More articles by this author Mariano Porras Department of Radiation Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain More articles by this author Juan J. Lobato Department of Urology, Hospital General Universitario de Alicante, Alicante, Spain More articles by this author María J. Ribal Department of Urology, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain More articles by this author Jacques Planas Department of Urology, Hospital Vall d’Hebron and Universitat Autónoma de Barcelona, Barcelona, Spain More articles by this author ANAMET Investigators Group More articles by this author Expand All Advertisement PDF downloadLoading ...